Program
guselkumab
Also written as “Guselkumab”, “Guselkumab Dose 1” and “Guselkumab Dose 2”.
Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.
Drug pageGuselkumab: every studyAll 80 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 5818 open or running | phase 4since Jun 3, 2021 | Sep 2, 2011 | Feb 10, 2027phase 3 · NCT06260163 |
| Eli Lillyits history only | 10 open or running | phase 4since Jun 20, 2018 | Jun 20, 2018 | none ahead |
| Surmount Services | 11 open or running | phase 1since Aug 20, 2026 | Aug 20, 2026 | Nov 20, 2026phase 1 · NCT07788807 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Surmount Services only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2026First study: phase 1 study in Healthy SubjectsFirst studyNCT07788807 · 18 planned · Australia
Ahead
- Nov 20, 2026Primary completion: phase 1 study in Healthy SubjectsNCT07788807
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risankizumabrule | AbbVie | phase 4 | 68 |
| mirikizumabrule | Eli Lilly | phase 4 | 36 |
Studies
The one study Surmount Services leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07788807Healthy Subjects · Australia | 1 | Recruiting | Nov 20, 2026 | 18 |
How it is read
Names in the registry
- “Guselkumab”, 43 entries
- “Guselkumab Dose 1”, 7 entries
- “Guselkumab Dose 2”, 7 entries
- “Guselkumab Dose 3”, 4 entries
- “Guselkumab 100 mg”, 2 entries
Conditions, from the studies’ own filings
- Psoriasis, 19 studies
- Crohn Disease, 11 studies
- Arthritis, Psoriatic, 10 studies
- Colitis, Ulcerative, 5 studies
- Arthritis, Juvenile, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.